Dr. Ikechukwu I. Akunyili
Claim this profileEphrata Cancer Center
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
3 reported clinical trials
8 drugs studied
Area of expertise
1Non-Small Cell Lung Cancer
Stage IV
MET positive
KRAS positive
2Lung Cancer
Stage IV
MET positive
KRAS positive
Affiliated Hospitals
Clinical Trials Ikechukwu I. Akunyili is currently running
Ramucirumab + Pembrolizumab vs Chemotherapy
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non-small cell lung cancer than standard chemotherapy.
Recruiting2 awards Phase 310 criteria
Tepotinib + Ramucirumab
for Lung Cancer
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal MET protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving tepotinib with ramucirumab may lower the chance of the cancer from growing or spreading in patients with stage IV or recurrent non-small cell lung cancer.
Recruiting1 award Phase 24 criteria
More about Ikechukwu I. Akunyili
Clinical Trial Related1 year of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Ikechukwu I. Akunyili has experience with
- Ramucirumab
- Data Collection
- Quality-of-Life Assessment
- Questionnaire Administration
- Biospecimen Collection
- Pembrolizumab
Breakdown of trials Ikechukwu I. Akunyili has run
Non-Small Cell Lung Cancer
Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ikechukwu I. Akunyili specialize in?
Ikechukwu I. Akunyili focuses on Non-Small Cell Lung Cancer and Lung Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage IV patients, or patients who are MET positive.
Is Ikechukwu I. Akunyili currently recruiting for clinical trials?
Yes, Ikechukwu I. Akunyili is currently recruiting for 2 clinical trials in Ephrata Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Ikechukwu I. Akunyili has studied deeply?
Yes, Ikechukwu I. Akunyili has studied treatments such as Ramucirumab, Data Collection, Quality-of-Life Assessment.
What is the best way to schedule an appointment with Ikechukwu I. Akunyili?
Apply for one of the trials that Ikechukwu I. Akunyili is conducting.
What is the office address of Ikechukwu I. Akunyili?
The office of Ikechukwu I. Akunyili is located at: Ephrata Cancer Center, Ephrata, Pennsylvania 17522 United States. This is the address for their practice at the Ephrata Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.